Korea United Pharm Inc
KRX:033270
Korea United Pharm Inc
KRX:033270
Price:
20 550
KRW
-1.44%
Market Cap:
302.3B
KRW
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
Alert
Korea United Pharm Inc
20550
-300 (-1.44%)
| 52 Week Range |
20 550
27 550
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
Korea United Pharm Inc
Balance Sheet
Balance Sheet Decomposition
Korea United Pharm Inc
Korea United Pharm Inc
| Current Assets | 245.1B |
| Cash & Short-Term Investments | 133.8B |
| Receivables | 49.3B |
| Other Current Assets | 62.1B |
| Non-Current Assets | 240.9B |
| Long-Term Investments | 74.2B |
| PP&E | 151B |
| Intangibles | 9.2B |
| Other Non-Current Assets | 6.5B |
| Current Liabilities | 79.8B |
| Accounts Payable | 16.6B |
| Accrued Liabilities | 18.1B |
| Other Current Liabilities | 45B |
| Non-Current Liabilities | 19.6B |
| Long-Term Debt | 14.7B |
| Other Non-Current Liabilities | 4.9B |
Balance Sheet
Korea United Pharm Inc
Korea United Pharm Inc
Currency: KRW
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
31 118
|
22 877
|
18 393
|
10 008
|
24 310
|
40 004
|
40 481
|
60 829
|
26 896
|
23 914
|
|
| Cash |
30
|
28
|
16
|
12
|
22
|
14
|
25
|
20
|
32
|
24
|
|
| Cash Equivalents |
31 088
|
22 849
|
18 377
|
9 996
|
24 288
|
39 990
|
40 456
|
60 808
|
26 864
|
23 889
|
|
| Short-Term Investments |
11 719
|
17 774
|
23 855
|
32 013
|
36 851
|
37 762
|
53 764
|
62 374
|
115 736
|
127 138
|
|
| Total Receivables |
41 129
|
45 541
|
45 090
|
51 473
|
51 559
|
46 274
|
40 088
|
36 993
|
40 533
|
43 454
|
|
| Accounts Receivables |
39 514
|
42 748
|
42 772
|
48 963
|
49 494
|
45 869
|
39 553
|
35 904
|
40 117
|
42 087
|
|
| Other Receivables |
1 615
|
2 793
|
2 318
|
2 510
|
2 065
|
405
|
535
|
1 089
|
416
|
1 367
|
|
| Inventory |
27 209
|
25 619
|
27 683
|
33 835
|
39 472
|
40 117
|
46 015
|
42 434
|
41 067
|
49 142
|
|
| Other Current Assets |
252
|
321
|
364
|
487
|
263
|
361
|
576
|
1 728
|
161
|
1 086
|
|
| Total Current Assets |
111 427
|
112 132
|
115 385
|
127 816
|
152 455
|
164 517
|
180 924
|
204 357
|
224 392
|
244 735
|
|
| PP&E Net |
67 003
|
76 602
|
77 255
|
95 823
|
106 538
|
120 173
|
123 631
|
120 804
|
136 445
|
155 279
|
|
| PP&E Gross |
67 003
|
76 602
|
77 255
|
95 823
|
106 538
|
120 173
|
123 631
|
120 804
|
136 445
|
155 279
|
|
| Accumulated Depreciation |
42 259
|
44 223
|
42 346
|
47 065
|
53 043
|
58 310
|
65 418
|
71 179
|
73 213
|
81 011
|
|
| Intangible Assets |
3 572
|
4 401
|
5 476
|
6 496
|
5 549
|
5 987
|
6 223
|
7 268
|
8 808
|
9 343
|
|
| Note Receivable |
5 196
|
4 248
|
417
|
640
|
0
|
2 180
|
3 108
|
3 183
|
3 112
|
2 056
|
|
| Long-Term Investments |
27 300
|
32 282
|
34 854
|
34 062
|
36 520
|
37 760
|
38 723
|
43 571
|
44 425
|
56 638
|
|
| Other Long-Term Assets |
2 602
|
844
|
833
|
960
|
894
|
627
|
823
|
849
|
709
|
809
|
|
| Total Assets |
217 101
N/A
|
230 509
+6%
|
234 220
+2%
|
265 796
+13%
|
301 955
+14%
|
331 244
+10%
|
353 433
+7%
|
380 033
+8%
|
417 891
+10%
|
468 860
+12%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
4 995
|
6 775
|
6 099
|
6 829
|
7 168
|
7 389
|
5 879
|
6 359
|
8 354
|
8 096
|
|
| Accrued Liabilities |
10 572
|
11 857
|
13 149
|
15 652
|
15 488
|
15 044
|
15 032
|
17 277
|
18 952
|
19 034
|
|
| Short-Term Debt |
3 282
|
7 280
|
7 645
|
10 606
|
18 537
|
18 500
|
21 568
|
16 000
|
16 000
|
23 500
|
|
| Current Portion of Long-Term Debt |
1 708
|
7 200
|
3 000
|
7 572
|
3 350
|
2 278
|
2 913
|
4 020
|
6 067
|
5 007
|
|
| Other Current Liabilities |
7 868
|
5 562
|
9 744
|
9 501
|
15 530
|
15 489
|
14 400
|
17 198
|
16 507
|
16 959
|
|
| Total Current Liabilities |
28 425
|
38 674
|
39 637
|
50 160
|
60 073
|
58 700
|
59 791
|
60 855
|
65 880
|
72 595
|
|
| Long-Term Debt |
19 779
|
13 392
|
10 572
|
7 000
|
6 650
|
11 885
|
11 386
|
12 971
|
8 232
|
11 832
|
|
| Deferred Income Tax |
3 573
|
2 935
|
2 138
|
1 470
|
598
|
620
|
472
|
187
|
746
|
877
|
|
| Minority Interest |
7
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
3 490
|
3 517
|
4 486
|
5 485
|
6 151
|
4 939
|
4 893
|
5 312
|
5 176
|
4 875
|
|
| Total Liabilities |
55 273
N/A
|
58 518
+6%
|
56 833
-3%
|
64 115
+13%
|
73 472
+15%
|
76 145
+4%
|
76 542
+1%
|
79 324
+4%
|
80 034
+1%
|
90 179
+13%
|
|
| Equity | |||||||||||
| Common Stock |
8 104
|
8 104
|
8 104
|
8 104
|
8 104
|
8 116
|
8 122
|
8 122
|
8 122
|
8 122
|
|
| Retained Earnings |
136 528
|
155 072
|
171 196
|
195 359
|
222 098
|
248 128
|
269 848
|
293 301
|
333 084
|
375 463
|
|
| Additional Paid In Capital |
17 719
|
17 722
|
17 860
|
18 016
|
18 074
|
18 645
|
19 121
|
18 730
|
18 730
|
18 730
|
|
| Unrealized Security Profit/Loss |
2 348
|
2 348
|
2 349
|
2 336
|
2 338
|
2 341
|
1 933
|
1 962
|
1 968
|
1 987
|
|
| Treasury Stock |
2 731
|
11 149
|
22 164
|
22 164
|
22 164
|
22 164
|
22 164
|
22 164
|
25 211
|
27 169
|
|
| Other Equity |
141
|
105
|
43
|
32
|
32
|
33
|
31
|
757
|
1 163
|
1 547
|
|
| Total Equity |
161 828
N/A
|
171 991
+6%
|
177 387
+3%
|
201 682
+14%
|
228 482
+13%
|
255 099
+12%
|
276 891
+9%
|
300 709
+9%
|
337 856
+12%
|
378 681
+12%
|
|
| Total Liabilities & Equity |
217 101
N/A
|
230 509
+6%
|
234 220
+2%
|
265 796
+13%
|
301 955
+14%
|
331 244
+10%
|
353 433
+7%
|
380 033
+8%
|
417 891
+10%
|
468 860
+12%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
16
|
15
|
15
|
15
|
15
|
15
|
15
|
15
|
15
|
15
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
